These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 25818733)

  • 1. A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.
    Wu MD; Wang Y; Ding T; Zhou YF; Song J; Liu XH; Wei MH; Yang QH; Zhou J; Wang SH; Lv QY
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e103-5. PubMed ID: 25818733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
    Li Y; Yang Y; Shang YM; Zheng H
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
    Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C
    Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
    Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
    Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
    Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
    Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
    Eisenhauer EL; Zanagnolo V; Cohn DE; Salani R; O'Malley DM; Sutton G; Callahan MJ; Cobb B; Fowler JM; Copeland LJ
    Gynecol Oncol; 2014 Aug; 134(2):262-6. PubMed ID: 24910452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
    Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
    Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
    Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
    Sehouli J; Stengel D; Oskay G; Camara O; Hindenburg HJ; Klare P; Blohmer J; Heinrich G; Elling D; Ledwon P; Lichtenegger W;
    Ann Oncol; 2002 Nov; 13(11):1749-55. PubMed ID: 12419747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
    Brufsky A; Hoelzer K; Beck T; Whorf R; Keaton M; Nadella P; Krill-Jackson E; Kroener J; Middleman E; Frontiera M; Paul D; Panella T; Bromund J; Zhao L; Orlando M; Tai F; Marciniak MD; Obasaju C; Hainsworth J
    Clin Breast Cancer; 2011 Aug; 11(4):211-20. PubMed ID: 21723792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
    Richardson DL; Backes FJ; Seamon LG; Zanagnolo V; O'Malley DM; Cohn DE; Fowler JM; Copeland LJ
    Gynecol Oncol; 2008 Dec; 111(3):461-6. PubMed ID: 18829088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
    Gallego A; Ramon-Patino J; Brenes J; Mendiola M; Berjon A; Casado G; Castelo B; Espinosa E; Hernandez A; Hardisson D; Feliu J; Redondo A
    Clin Transl Oncol; 2021 Mar; 23(3):536-542. PubMed ID: 32651885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.
    Pinilla-Dominguez P; Richardson J; Robertson J; Adam J
    Lancet Oncol; 2013 Jul; 14(8):691-2. PubMed ID: 23706986
    [No Abstract]   [Full Text] [Related]  

  • 15. Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.
    Takasaki K; Miyamoto M; Takano M; Soyama H; Aoyama T; Matsuura H; Kato K; Sakamoto T; Kuwahara M; Iwahashi H; Ishibashi H; Yoshikawa T; Furuya K
    Cancer Chemother Pharmacol; 2018 May; 81(5):809-814. PubMed ID: 29500481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols.
    Sattar S; Ahmad M; Saeed H; Saleem Z; Danish Z; Akhlaq M
    Acta Pharm; 2019 Mar; 69(1):87-97. PubMed ID: 31259718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
    Lee JY; Park JY; Park SY; Lee JW; Kim JW; Kim YB; Jeong DH; Lee KB; Kim TH; Lee IH; Choi MC; Kim KH; Kim YM; Lee YJ; Kang S; ; Pujade-Lauraine E
    Gynecol Oncol; 2019 Jan; 152(1):61-67. PubMed ID: 30409490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of platinum-sensitive recurrent ovarian cancer.
    Pfisterer J; Ledermann JA
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.